Matching insurance claims data with EMR molecular status data in non-small cell lung cancer (NSCLC) patients: Understanding real-world molecular testing and prevalence rates at the site and investigator level.

Michael Gregory Cushion,Bhavani Krishnan,Jeff Paul Hodge,Jaya Chandra Balusu,Joseph Wagner,Cristina Oliva,Dana Edwards

Matching insurance claims data with EMR molecular status data in non-small cell lung cancer (NSCLC) patients: Understanding real-world molecular testing and prevalence rates at the site and investigator level.

2019

Michael Gregory Cushion
Bhavani Krishnan
Jeff Paul Hodge
Jaya Chandra Balusu
Joseph Wagner
Cristina Oliva
Dana Edwards

e20568Background: Many targeted therapy clinical trials require a somatic gene mutation/alteration for eligibility. We assessed the feasibility of leveraging Real-World Data (RWD) to enrol NSCLC pa...

Keywords:

Prevalence
Oncology
non-small cell lung cancer (NSCLC)
Pathology
Internal medicine
Medicine
insurance claims
Targeted therapy
Somatic cell
Physical therapy
Clinical trial
gene mutation

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations